Published in J Infect Dis on August 15, 2010
Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity (2010) 3.25
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis (2012) 2.89
Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS (2014) 2.04
Neutralizing antibodies to HIV-1 induced by immunization. J Exp Med (2013) 1.59
How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? AIDS Res Hum Retroviruses (2011) 1.30
Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16. J Virol (2011) 1.19
The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection. J Virol (2011) 1.13
Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA. J Virol (2011) 1.13
B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. Trends Mol Med (2010) 1.11
Human immunodeficiency virus vaccine trials. Cold Spring Harb Perspect Med (2012) 1.05
Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates. Vaccines (Basel) (2014) 1.04
Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system. PLoS One (2013) 1.04
Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity. J Virol (2015) 1.01
Novel directions in HIV-1 vaccines revealed from clinical trials. Curr Opin HIV AIDS (2013) 1.01
Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission. J Clin Invest (2015) 0.98
HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies. Trends Immunol (2016) 0.97
Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies. J Virol (2014) 0.96
Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milk. J Virol (2013) 0.95
Immunoglobulin-specific responses to Chlamydia elementary bodies in individuals with and at risk for genital chlamydial infection. J Infect Dis (2012) 0.94
Novel HIV vaccine strategies: overview and perspective. Ther Adv Vaccines (2013) 0.90
Measurements of immune responses for establishing correlates of vaccine protection against HIV. AIDS Res Hum Retroviruses (2011) 0.90
Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein. Vaccine (2012) 0.86
Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routes. J Virol (2014) 0.86
Engineering broadly neutralizing antibodies for HIV prevention and therapy. Adv Drug Deliv Rev (2016) 0.86
A comparative study of stress-mediated immunological functions with the adjuvanticity of alum. J Biol Chem (2012) 0.85
Breakthrough Virus Neutralization Resistance as a Correlate of Protection in a Nonhuman Primate Heterologous Simian Immunodeficiency Virus Vaccine Challenge Study. J Virol (2015) 0.84
Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research. J Virol (2015) 0.84
Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens. Vaccines (Basel) (2013) 0.83
Native-like Env trimers as a platform for HIV-1 vaccine design. Immunol Rev (2017) 0.83
The role of innate APOBEC3G and adaptive AID immune responses in HLA-HIV/SIV immunized SHIV infected macaques. PLoS One (2012) 0.82
The role of neutralizing antibodies in prevention of HIV-1 infection: what can we learn from the mother-to-child transmission context? Retrovirology (2013) 0.82
Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C. PLoS One (2013) 0.81
Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques. Mol Ther (2016) 0.81
Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies. J Virol (2012) 0.81
HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development. Curr HIV Res (2013) 0.80
Lessons learned from HIV vaccine clinical efficacy trials. Curr HIV Res (2013) 0.79
Design of lipid nanocapsule delivery vehicles for multivalent display of recombinant Env trimers in HIV vaccination. Bioconjug Chem (2014) 0.79
Conformational instability governed by disulfide bonds partitions the dominant from subdominant helper T-cell responses specific for HIV-1 envelope glycoprotein gp120. Vaccine (2015) 0.78
Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions. J Transl Med (2013) 0.77
Importance of neutralization sieve analyses when seeking correlates of HIV-1 vaccine efficacy. Hum Vaccin Immunother (2014) 0.76
In silico design of a DNA-based HIV-1 multi-epitope vaccine for Chinese populations. Hum Vaccin Immunother (2015) 0.76
Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies. Immunol Rev (2017) 0.76
Complex immune correlates of protection in HIV-1 vaccine efficacy trials. Immunol Rev (2017) 0.76
Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene. J Infect Dis (2016) 0.75
The quest for an antibody-based HIV vaccine. Immunol Rev (2017) 0.75
Impact of gp120 on dendritic cell-derived chemokines: relevance for the efficacy of gp120-based vaccines for HIV-1. Clin Vaccine Immunol (2012) 0.75
Lessons learned from human HIV vaccine trials. Curr Opin HIV AIDS (2017) 0.75
Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes. Vaccine (2014) 0.75
Natural infection as a blueprint for rational HIV vaccine design. Hum Vaccin Immunother (2016) 0.75
Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments. J Virol (2017) 0.75
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science (2009) 17.14
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol (2005) 15.61
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother (2002) 13.91
Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A (2003) 12.75
The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science (1998) 12.52
Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol (1998) 10.94
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis (2005) 10.20
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature (2002) 9.62
Diversity considerations in HIV-1 vaccine selection. Science (2002) 9.60
HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 8.99
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis (2006) 7.98
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med (2009) 6.14
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol (2009) 5.91
Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis (2005) 5.14
Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med (2005) 4.68
The role of antibodies in HIV vaccines. Annu Rev Immunol (2010) 4.50
Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull (2001) 4.41
Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J Virol (1994) 3.70
Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol (2006) 3.34
HIV vaccines. Annu Rev Immunol (2006) 3.31
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2000) 3.13
Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol (2006) 2.72
Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype. J Infect Dis (1994) 2.42
Understanding the genetic diversity of HIV-1. AIDS (2000) 2.39
The rational design of an AIDS vaccine. Cell (2006) 2.11
HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS (2007) 1.99
Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development. AIDS Res Hum Retroviruses (1994) 1.83
HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. J Infect Dis (2005) 1.70
High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology (2009) 1.58
Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. Virology (2009) 1.51
Comparisons of two-part models with competitors. Stat Med (2001) 1.47
Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. Hum Antibodies (2005) 1.46
Urgently needed: a filter for the HIV-1 vaccine pipeline. Nat Med (2004) 1.30
Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. J Infect Dis (2004) 1.28
Development of an HIV-1 reference panel of subtype B envelope clones isolated from the plasma of recently infected individuals. J Acquir Immune Defic Syndr (2007) 1.27
Antibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization. J Virol (2006) 1.23
Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand. Virology (1999) 1.12
Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3. AIDS Res Hum Retroviruses (1998) 1.12
Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. AIDS Res Hum Retroviruses (1998) 1.10
Simultaneous Evaluation of the Magnitude and Breadth of a Left and Right Censored Multivariate Response, with Application to HIV Vaccine Development. Stat Biopharm Res (2009) 0.99
Ethnic differences in the adaptation rate of HIV gp120 from a vaccine trial. Retrovirology (2009) 0.93
Phylodynamics of HIV-1 from a phase-III AIDS vaccine trial in North America. Mol Biol Evol (2009) 0.87
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science (2009) 17.14
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol (2005) 15.61
Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98
Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A (2003) 12.75
Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature (2002) 12.49
Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature (2011) 11.07
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 8.99
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis (2006) 7.98
Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature (2002) 7.41
Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis (2008) 6.43
Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature (2008) 6.17
Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science (2006) 6.06
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol (2009) 5.91
Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One (2010) 5.73
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol (2008) 5.69
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature (2013) 5.35
Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis (2005) 5.14
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity (2013) 4.82
Standardization of cytokine flow cytometry assays. BMC Immunol (2005) 4.55
The role of antibodies in HIV vaccines. Annu Rev Immunol (2010) 4.50
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol (2003) 4.49
Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol (2005) 4.35
Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet (2005) 4.21
HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature (2002) 4.20
Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother (2006) 4.14
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol (2011) 4.06
Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A (2005) 3.94
The prevalence of antiretroviral drug resistance in the United States. AIDS (2004) 3.90
Comparison of HIV type 1 incidence observed during longitudinal follow-up with incidence estimated by cross-sectional analysis using the BED capture enzyme immunoassay. AIDS Res Hum Retroviruses (2006) 3.74
Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol (2009) 3.36
Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Vaccine (2006) 3.29
A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology (2006) 3.26
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med (2013) 3.24
Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. Sci Transl Med (2011) 3.08
Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J Virol (2002) 2.89
Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol (2005) 2.89
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis (2012) 2.89
Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J Virol (2005) 2.83
Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev Vaccines (2006) 2.79
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol (2012) 2.74
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med (2011) 2.71
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A (2013) 2.69
Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J Virol (2004) 2.63
Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology (2010) 2.61
Dynamic immune responses maintain cytotoxic T lymphocyte epitope mutations in transmitted simian immunodeficiency virus variants. Nat Immunol (2005) 2.60
Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS (2009) 2.53
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med (2014) 2.47
Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis (2004) 2.47
Prospects for vaccine protection against HIV-1 infection and AIDS. Annu Rev Immunol (2001) 2.43
Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol (2011) 2.42
Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology (2008) 2.37
In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J Virol (2009) 2.29
Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother (2002) 2.21
High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A (2011) 2.14
Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J Virol (2002) 2.13
Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. Virology (2006) 2.07
Motivations for participating in an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr (2005) 2.04
Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS (2014) 2.04
International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One (2009) 2.03
Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques. J Virol (2005) 2.01
Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol (2002) 1.97
Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med (2011) 1.97
Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J Infect Dis (2010) 1.95
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses (2012) 1.94
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One (2013) 1.94
Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses. J Immunol (2002) 1.89
International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine (2011) 1.88
Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev Vaccines (2006) 1.88
Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc Natl Acad Sci U S A (2009) 1.87
Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol (2007) 1.87
Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. J Virol (2012) 1.86
Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nat Med (2012) 1.86
A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One (2011) 1.81
Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J Virol (2007) 1.81
Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J Virol (2004) 1.80